VarDict: A novel and versatile variant caller for next-generation sequencing in cancer research

Nucleic Acids Research

Volumn 44, Issue 11, 2016, Pages

  Lai, Zhongwu ^a   Markovets, Aleksandra ^a   Ahdesmaki, Miika ^a   Chapman, Brad ^b   Hofmann, Oliver ^b,c   Mcewen, Robert ^a   Johnson, Justin ^a   Dougherty, Brian ^a   Barrett, J Carl ^a   Dry, Jonathan R ^a  

^a ASTRAZENECA   (United Kingdom)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ALLELE; AMPLICON; ARTICLE; BRAF GENE; CANCER GENETICS; CANCER RESEARCH; CIRCULATING TUMOR CELL; COMPUTER PROGRAM; CONTROLLED STUDY; DNA SEQUENCE; EGFR GENE; GENE FREQUENCY; GENETIC DATABASE; GENETIC VARIABILITY; HETEROZYGOSITY LOSS; HUMAN; KRAS GENE; MET GENE; NEXT GENERATION SEQUENCING; ONCOGENE; PATIENT; PERFORMANCE; PIK3CA GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SEQUENCE; BIOLOGY; GENETIC VARIATION; GENETICS; HIGH THROUGHPUT SEQUENCING; INDEL MUTATION; LUNG TUMOR; NEOPLASM; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; RESEARCH; SOFTWARE;

ALLELES; COMPUTATIONAL BIOLOGY; GENE FREQUENCY; GENETIC VARIATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDEL MUTATION; LOSS OF HETEROZYGOSITY; LUNG NEOPLASMS; NEOPLASMS; RESEARCH; ROC CURVE; SEQUENCE ANALYSIS, DNA; SOFTWARE;

EID: 84976448371     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkw227     Document Type: Article

References (32)

1. TCGA. (2011). Integrated genomic analysis of ovarian carcinoma. Nature, 474, 609-615.
2. Frampton G.M, Fichtenholtz A, Otto G.A, Wang K, Downing S.R, He J, Schnall-Levin M, White J, Sanford E.M, An P, et al. (2013). Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol, 31, 1023-1031.
3. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, et al. (2010). The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res, 20, 1297-1303.
4. Koboldt D.C, Zhang Q, Larson D.E, Shen D, Mclellan M.D, Lin L, Miller C.A, Mardis E.R, Ding L, and Wilson R.K. (2012). VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res, 22, 568-576.
5. Forbes S.A, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, Ding M, Bamford S, Cole C, Ward S, et al. (2015). COSMIC: exploring the worlds knowledge of somatic mutations in human cancer. Nucleic Acids Res, 43, D805-D811.
6. Harismendy O, Schwab R.B, Alakus H, Yost S.E, Matsui H, Hasteh F, Wallace A.M, Park H.L, Madlensky L, Parker B, et al. (2013). Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. Breast Cancer Res, 15, R115.
7. Marchetti A, Palma J.F, Felicioni L, De Pas T.M, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes A.A, Chella A, et al. (2015). Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J. Thorac Oncol, 10, 1437-1443.
8. Li H, and Durbin R. (2009). Fast and accurate short read alignment with Burrows-Wheeler Transform. Bioinformatics, 25, 1754-1760.
9. Langmead B, Trapnell C, Pop M, and Salzberg S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Gen Biol, 10, R25.
10. Langmead B, and Salzberg S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat. Meth, 9, 357-359.
11. Trapnell C, Pachter L, and Salzberg S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. Bioinformatics, 25, 1105-1111.
12. Dobin A, Davis C.A, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, and Gingeras T.R. (2013). STAR: ultrafast universal RNA-seq aligner. Bioinformatics, 29, 15-21.
13. Robinson J.T, Thorvaldsdóttir H, Winckler W, Guttman M, Lander E.S, Getz G, and Mesirov J.P. (2011). Integrative Genomics Viewer. Nat. Biotechnology, 29, 24-26.
14. TCGA. (2014). Comprehensive molecular profiling of lung adenocarcinoma. Nature, 511, 543-550.
15. Thress K.S, Paweletz C.P, Felip E, Cho B.C, Stetson D, Dougherty B, Lai Z, Markovets A, Vivancos A, Kuang Y, et al. (2015). Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harbouring EGFR T790M. Nat. Med, 21, 560-562.
16. Lynch T.J, Bell D.W, Sordella R, Gurubhagavatula S, Okimoto R.A, Brannigan B.W, Harris P.L, Haserlat S.M, Supko J.G, Haluska F.G, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N. Engl. J. Med, 350, 2129-2139.
17. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Rulton L, et al. (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A, 101, 13306-13311.
18. Huang W, Li L, Myers J.R, and Marth G.T. (2012). ART: a next-generation sequencing read simulator. Bioinformatics, 28, 593-594.
19. Ye K, Schulz M.H, Long Q, Apweiler R, and Ning Z. (2009). Pindel: a pattern growth approach to detect breakpoints of large deletions and medium sized insertions from paired-end short reads. Bioinformatics, 25, 2865-2871.
20. Narzisi G, ORawe J.A, Iossifov I, Fang H, Lee Y, Wang Z, Wu Y, Lyon G.J, Wigler M, and Schatz M.C. (2014). Accurate de novo and transmitted indel detection in exome-capture data using microassembly. Nat. Methods, 11, 1003-1036.
21. Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, Cox A.J, Kruglyak S, and Saunders C.T. (2015). Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics, 2015, btv710.
22. Layer R.M, Chiang C, Quinlan A.R, and Hall I.M. (2014). LUMPY: a probabilistic framework for structural variant discovery. Genome Biol, 15, R84.
23. Ewing A.D, Houlahan K.E, Hu Y, Ellrott K, Caloian C, Yamaguchi T.N, Bare J.C, Png C, Waggott D, Sabelnykova V.Y, et al. (2015). Combining tumor genome simulation with crowdsourcing to benchmark somatic single-nucleotide-variant detection. Nat. Methods, 12, 623-630.
24. Gao J, Aksoy B.A, Dogrusoz U, Dresdner G, Gross B, Sumer S.O, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal, 6, pl1.
25. Park J.Y, Kricka L.J, and Fortina P. (2013). Next-generation sequencing in the clinic. Nat. Biotechnol, 31, 990-992.
26. Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med, 366, 1382-1392.
27. Fang L.T, Afshar P.T, Chhibber A, Mohiyuddin M, Fan Y, Mu J.C, Gibeling G, Barr S, Asadi N.B, Gerstein M.B, et al. (2015). An ensemble approach to accurately detect somatic mutations using SomaticSeq. Genome Biol, 16, 197.
28. Karapetis C.S, Khambata-Ford S, Jonker D.J, OCallaghan C.J, Tu D, Tebbutt N.C, Simes R.J, Chalchal H, Shapiro J.D, Robitaille S, et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med, 359, 1757-1765.
29. Bardelli A, and Siena S. (2010). Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol, 28, 1254-1261.
30. Soda M, Choi Y.L, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 448, 561-566.
31. Davies K.D, Le A.T, Theodoro M.F, Skokan M.C, Aisner D.L, Berge E.M, Terracciano L.M, Cappuzzo F, Incarbone M, Roncalli M, et al. (2012). Identifying and targeting ROS1 gene fusion in non-small cell lung cancer. Clin. Cancer Res, 18, 4570-4579.
32. Judkins T, Rosenthal E, Amell C, Burbidge L.A, Geary W, Barrus T, Schoenberger J, Trost J, Wenstrup R.J, and Roa B.B. (2012). Clinical significance of large rearrangements in BRCA1 and BRCA2. Cancer, 118, 5210-5216.